Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision-making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ
Format:	Journal article
Język:	English
Wydane:	Wiley 2016

Podobne zapisy

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
od: Sonya Cressman, i wsp.
Wydane: (2020-07-01)

Hypocellular Acute Myeloid Leukaemia-A Diagnostic Conundrum
od: Sindhura Lakshmi Koulmane Laxminarayana, i wsp.
Wydane: (2018-12-01)

Acute Myeloid Leukaemia with Plasmacytosis
od: Yasmin Akhtar, Saqib Qayyum Ahmad, Shahid Jamal
Wydane: (2016-12-01)

Exploring the acute myeloid leukaemias
od: TB Thapa
Wydane: (2013-10-01)

Secondary acute myeloid leukaemia in children treated for acute lymphoblastic leukaemia.
od: Eden, O, i wsp.
Wydane: (1998)

Acute myeloid leukaemia with aberrant expression of pancytokeratin: A diagnostic pitfall
od: Yasin Dhonye, i wsp.
Wydane: (2023-02-01)

DISTINCTION BETWEEN ACUTE MYELOID LEUKAEMIA WITH MYELODYSPLASIA-RELATED CHANGES AND MIXED-PHENOTYPE ACUTE LEUKAEMIA: A DIAGNOSTIC CHALLENGE
od: NA Marcondes, i wsp.
Wydane: (2021-10-01)

Harnessing the graft-versus-leukaemia effect in acute myeloid leukaemia
od: Sweeney, C
Wydane: (2021)

Adhesion Deregulation in Acute Myeloid Leukaemia
od: Alicja M. Gruszka, i wsp.
Wydane: (2019-01-01)

Wnt Signalling in Acute Myeloid Leukaemia
od: Alicja M. Gruszka, i wsp.
Wydane: (2019-11-01)

Orbital deposit in acute myeloid leukaemia
od: Seal G, i wsp.
Wydane: (1973-01-01)

Prediction of acute myeloid leukaemia risk in healthy individuals
od: Abelson, S, i wsp.
Wydane: (2018)

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.
od: Guinn, B, i wsp.
Wydane: (2005)

Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia
od: Sitânia Chiesa, i wsp.
Wydane: (2024-12-01)

Amplification of mitochondrial DNA in acute myeloid leukaemia.
od: Boultwood, J, i wsp.
Wydane: (1996)

Immunological weapons against acute myeloid leukaemia.
od: Galea-Lauri, J
Wydane: (2002)

C/EBPalpha mutations in acute myeloid leukaemias.
od: Nerlov, C
Wydane: (2004)

EVI1 expression in acute myeloid leukaemia.
od: Langabeer, SE, i wsp.
Wydane: (2001)

New Therapeutic Approaches for Acute Myeloid Leukaemia
od: Ruth M Risueno, i wsp.
Wydane: (2021-06-01)

Acute Myeloid Leukaemia Presenting as Gaze Palsy
od: Evripidis Sykakis, i wsp.
Wydane: (2011-11-01)

Pharmacogenomics and regulation of apoptosis in acute myeloid leukaemia
od: Pravdić Zlatko, i wsp.
Wydane: (2020-01-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
od: R Edlin, i wsp.
Wydane: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
od: R Edlin, i wsp.
Wydane: (2010-05-01)

Expression of Aberrant Markers and its Association with Remission Postinduction Therapy in Acute Lymphoblastic Leukaemia and Acute Myeloid Leukaemia
od: Subbaramaiah Shwetha, i wsp.
Wydane: (2021-07-01)

P580: THE USE OF LEUKAEMIA Q-FUSION GENE SCREENING ASSAY (Q30) IN THE DIAGNOSTIC EVALUATION OF ACUTE MYELOID LEUKAEMIA (AML)
od: S. Tayabali, i wsp.
Wydane: (2022-06-01)

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia
od: Jakobsen, N, i wsp.
Wydane: (2018)

OUTCOME OF CHEMOTHERAPY IN NON ACUTE PROMYELOCYTIC ACUTE MYELOID LEUKAEMIA
od: Nighat Shahbaz, i wsp.
Wydane: (2020-10-01)

OUTCOME OF CHEMOTHERAPY IN NON ACUTE PROMYELOCYTIC ACUTE MYELOID LEUKAEMIA
od: Nighat Shahbaz, i wsp.
Wydane: (2020-10-01)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
od: Boultwood, J, i wsp.
Wydane: (2004)

Less utilized prognostic markers in acute myeloid leukaemia
od: Abdullah, Maha
Wydane: (2016)

Improved outcome of acute myeloid leukaemia in Down's syndrome.
od: Craze, J, i wsp.
Wydane: (1999)

Randomised studies in acute myeloid leukaemia: the double truth
od: Richards, S
Wydane: (2000)

Detection of Cup-like Blasts in Acute Myeloid Leukaemia
od: Supriya Mehrotra, i wsp.
Wydane: (2019-10-01)

Phlegmonous gastritis as the initial presentation of acute myeloid leukaemia
od: Shin Lee, i wsp.
Wydane: (2022-08-01)

Chronic myeloid leukaemia presenting as acute pulmonary thromboembolism
od: Shetty Mallikarjuna, i wsp.
Wydane: (2022-01-01)

Granulocytic Sarcoma in an Adult with Relapsed Acute Myeloid Leukaemia
od: Neethu Ann Kurien, i wsp.
Wydane: (2016-01-01)

Unilateral proptosis: extramedullary manifestation of acute myeloid leukaemia
od: Pallavi Gahlowt, i wsp.
Wydane: (2016-03-01)

Clinico-haematological and Cytochemical Study of Acute Myeloid Leukaemia
od: Anil Meena, i wsp.
Wydane: (2020-10-01)

Transcriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia
od: Shaun D. Patterson, i wsp.
Wydane: (2021-08-01)

ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia
od: Mohd Amin, A, i wsp.
Wydane: (2023)